- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6653
Provisional Schedule
- Committee meeting: 1:
- 10 December 2026
- Expected publication:
- 28 January 2027
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email TACommB@nice.org.uk
- External Assessment Group:
- Warwick Evidence, Warwick Medical School, University of Warwick
Stakeholders
- Companies sponsors
- Pfizer (elranatamab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- African Caribbean Leukaemia Trust
- Anthony Nolan
- Black Health Agency for Equality
- Blood Cancer UK
- Cancer Black Care
- Cancer Equality
- Cancer52
- DKMS
- Independent Cancer Patients Voice
- Kevin Karawa Leukaemia Trust
- Leukaemia Cancer Society
- Leukaemia Care
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Myeloma UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- Professional groups
- Association of Cancer Physicians
- British Blood Transfusion Society
- British Committee for Standards in Haematology
- British Geriatrics Society
- British Institute of Radiology
- British Psychosocial Oncology Society
- British Society for Haematology
- British Transplantation Society
- Cancer Research UK
- NHS Blood and Transplant
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Myeloma Society
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- ADVANZ Pharma (dexamethasone)
- Amarox (lenalidomide, pomalidomide)
- Arcellx and Kite, Gilead Sciences (anitocabtagene autoleucel)
- Aspire Pharma (bortezomib, dexamethasone)
- Aurobindo Pharma (bortezomib)
- Biocon Pharma (lenalidomide)
- Biotech Pharma (bortezomib)
- Bristol Myers Squibb (mezigdomide)
- CNX Therapeutics (dexamethasone)
- Dr. Reddy's Laboratories UK (bortezomib)
- GlaxoSmithKline (belantamab mafodotin)
- Glenmark Pharmaceuticals Europe (dexamethasone)
- Grindeks Kalceks UK (lenalidomide, pomalidomide)
- Johnson & Johnson (bortezomib, ciltacabtagene autoleucel, daratumumab, talquetamab, teclistamab)
- Krka UK (dexamethasone)
- Menarini Stemline (selinexor)
- MSN Laboratories Europe (bortezomib)
- Pharmaand (panobinostat)
- Regeneron Pharmaceuticals (linvoseltamab)
- Sandoz (bortezomib)
- Sanofi (isatuximab)
- Sun Pharmaceuticals (bortezomib, lenalidomide)
- Takeda UK (ixazomib)
- Teva UK (lenalidomide)
- Thornton & Ross (bortezomib, lenalidomide, pomalidomide)
- Viatris (lenalidomide)
- Wockhardt UK (pomalidomide)
- Zentiva (dexamethasone, pomalidomide)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- Cochrane Haematological Malignancies Group
- Cochrane UK
- Genomics England
- Institute of Cancer Research
- Leukaemia Busters
- Leukaemia UK
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 May 2026 | In progress. ITP issued |
| 21 May 2026 | Invitation to participate |
| 02 April 2026 - 01 May 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 10 February 2026 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual